Nova Life Peptides has announced that one of the most widely recognized suppliers of research-grade peptides in the United States has permanently ceased operations. The company posted a brief notice on its website confirming a voluntary shutdown and the discontinuation of all product sales. No detailed explanation was provided, and no transition plan was announced — leaving tens of thousands of researchers, clinicians, and labs scrambling to replace a supplier many had relied on for years.
The closure marks one of the most significant disruptions the research peptide market has experienced, coming amid an unprecedented period of regulatory pressure. In 2024 and 2025, the FDA, Department of Justice, and FBI escalated enforcement actions targeting research chemical vendors. Major pharmaceutical companies, including Eli Lilly and Novo Nordisk, filed International Trade Commission complaints against vendors supplying GLP-1 analogs. The FDA moved dozens of peptides onto restricted lists before partially reversing course in February 2026, when HHS Secretary Robert F. Kennedy Jr. announced the restoration of compounding access for approximately 14 previously banned peptides.
The compounding effect of these pressures appears to have made continued operations untenable for many companies in the industry.
Industry Response
Kenneth Sabraw, owner of Nova Life Peptides — a US-based research peptide supplier headquartered in Murfreesboro, Tennessee — called the shutdown a watershed moment for the industry.
“This closure has sent a shockwave through the research community. Researchers who had built their protocols around a trusted supplier woke up one day and found the door locked with no warning. That’s a real disruption — not just an inconvenience. It’s a reminder that stability, transparency, and regulatory awareness aren’t optional in this space. They’re the foundation everything else is built on.”
— Kenneth Sabraw, Owner, Nova Life Peptides
Sabraw noted that the shutdown has accelerated demand for suppliers who combine quality standards with operational transparency.
“What this moment is teaching the market is that independent third-party testing, clear documentation, and US-based operations aren’t just nice-to-haves. They’re what separates suppliers who will be here in five years from those who won’t. We’ve been building Nova Life Peptides on exactly those principles, and we’re ready to serve the researchers who need a reliable home.”
— Kenneth Sabraw, Owner, Nova Life Peptides
About Nova Life Peptides
Nova Life Peptides is a US-based supplier of research-grade peptides for laboratory and scientific research applications. All products are manufactured to GMP Grade standards through ISO 9001-certified processes and verified to 99%+ purity through independent, third-party laboratory analysis. Every batch ships with a Certificate of Analysis (COA) confirming identity, purity, and consistency.
Media Contact: Kenneth Sabraw | Nova Life Peptides |1740 Old Fort Parkway, Suite 1001, Murfreesboro, TN 37129 | (615) 900-4392
The expert opinions presented in this press release are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of the news distribution company and its distribution partners. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any medical treatment, product, or service in this article. Moreover, nothing contained in this should be construed as medical advice or a recommendation to start, stop, or change any medical treatment or medication. It is your responsibility to determine whether any medical treatment, product, or service is appropriate for you based on your health objectives, medical condition, and risk tolerance. Consult your healthcare provider regarding your specific medical situation.